ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,277.51
0.80%
US Tech 100
18,064.80
0.02%
다우존스 지수
38,686.32
1.51%
Bitcoin
67,576.79
0.14%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 유럽
  5. EU
  6. Biosenic (BIOS)

  7. Biosenic (BIOS) 뉴스

BIOS

Biosenic (BIOS)

Biosenic
일자:
정렬 기준:
 검색 관련기사 보기:EU:BIOS
일자시간출처헤드라인심볼기업
2024/05/3114:00GlobeNewswire Inc.BioSenic S.A. : Information on the total number of voting rights and sharesEU:BIOSBiosenic
2024/05/3114:00GlobeNewswire Inc.BioSenic S.A. : Information relative au nombre total de droits de vote et d’actionsEU:BIOSBiosenic
2024/05/2800:00GlobeNewswire Inc.BioSenic S.A. : Positive vote of the majority of creditors in favor of the global restructuring plan of BioSenic covering the years 2024-2032, at the Enterprise Court of NivellesEU:BIOSBiosenic
2024/05/2800:00GlobeNewswire Inc.BioSenic S.A. : Vote positif de la majorité des créanciers en faveur du plan global de restructuration de BioSenic couvrant les années 2024-2032, au Tribunal d'Entreprise de NivellesEU:BIOSBiosenic
2024/05/2500:00GlobeNewswire Inc.BioSenic provides First Quarter 2024 Business UpdateEU:BIOSBiosenic
2024/05/2500:00GlobeNewswire Inc.BioSenic fait le point sur ses activités du premier trimestre 2024EU:BIOSBiosenic
2024/04/3014:00GlobeNewswire Inc.BioSenic S.A. : Information relative au nombre total de droits de vote et d’actionsEU:BIOSBiosenic
2024/04/3014:00GlobeNewswire Inc.BioSenic S.A. : Information on the total number of voting rights and sharesEU:BIOSBiosenic
2024/04/2700:30GlobeNewswire Inc.BioSenic publie sur son site web le plan de restructuration soumis au tribunal des entreprises de Nivelles  EU:BIOSBiosenic
2024/04/2700:30GlobeNewswire Inc.BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of NivellesEU:BIOSBiosenic
2024/04/2414:00GlobeNewswire Inc.BioSenic reporte son assemblée générale annuelle des actionnaires et fournit des chiffres financiers temporaires non-audités pour 2023EU:BIOSBiosenic
2024/04/2414:00GlobeNewswire Inc.BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023EU:BIOSBiosenic
2024/04/1814:00GlobeNewswire Inc.BioSenic S.A. : Notifications de transparence reçues de la part de François RiegerEU:BIOSBiosenic
2024/04/1814:00GlobeNewswire Inc.BioSenic S.A. : Transparency notifications received from François RiegerEU:BIOSBiosenic
2024/04/1219:00GlobeNewswire Inc.BioSenic provides further information on its restructuring planEU:BIOSBiosenic
2024/04/1219:00GlobeNewswire Inc.BioSenic fournit des informations complémentaires sur son plan de restructurationEU:BIOSBiosenic
2024/04/1121:00GlobeNewswire Inc.BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of NivellesEU:BIOSBiosenic
2024/04/1121:00GlobeNewswire Inc.BioSenic et son praticien de la restructuration (Me Yves Brulard) soumettent un plan de restructuration global engageant les années 2024-2030 au Tribunal de l’entreprise de NivellesEU:BIOSBiosenic
2024/03/2915:00GlobeNewswire Inc.BioSenic S.A. : Information relative au nombre total de droits de vote et d’actions  EU:BIOSBiosenic
2024/03/2915:00GlobeNewswire Inc.BioSenic S.A. : Information on the total number of voting rights and sharesEU:BIOSBiosenic
2024/03/2015:00GlobeNewswire Inc.BioSenic présente des données précliniques concluantes sur son médicament ATO pour le contrôle des principaux symptômes au Congrès mondial 2024 sur la sclérose systémiqueEU:BIOSBiosenic
2024/03/2015:00GlobeNewswire Inc.BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World CongressEU:BIOSBiosenic
2024/03/1215:00GlobeNewswire Inc.BioSenic publie les détails de la stratégie d'administration optimisée pour OATO dans le traitement de la maladie chronique du greffon contre l'hôte en amont du prochain essai de phase 3EU:BIOSBiosenic
2024/03/1215:00GlobeNewswire Inc.BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host diseaseEU:BIOSBiosenic
2024/02/2915:00GlobeNewswire Inc.BioSenic S.A. : Information on the total number of voting rights and sharesEU:BIOSBiosenic
2024/02/2915:00GlobeNewswire Inc.BioSenic S.A. : Information relative au nombre total de droits de vote et d’actionsEU:BIOSBiosenic
2024/02/0301:30GlobeNewswire Inc.BioSenic lève 500 000 euros dans le cadre d'un placement privé d'actions nouvelles auprès de nouveaux investisseurs établisEU:BIOSBiosenic
2024/02/0301:30GlobeNewswire Inc.BioSenic raises €500,000 in private placement of new shares with established new investorsEU:BIOSBiosenic
2024/01/3118:30GlobeNewswire Inc.BioSenic soutient la prochaine conférence européenne sur la maladie du greffon contre l'hôteEU:BIOSBiosenic
2024/01/3118:30GlobeNewswire Inc.BioSenic provides support to forthcoming European conference on graft-versus-host disease  EU:BIOSBiosenic
 검색 관련기사 보기:EU:BIOS

최근 히스토리

BIT
P200X3
NLBNPIT200X3 20991231 15...
BIT
P1UIZ9
NLBNPIT1UIZ9 20351221 41...
BIT
P1S1J0
NLBNPIT1S1J0 20240621 350
BIT
P1V7O2
NLBNPIT1V7O2 20351221 18...
BIT
P1WRL6
NLBNPIT1WRL6 20991231 46...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유